Kornimate/medical-research-clean huggingface dataset:
balloon-assisted enteroscopy and bacteria

Conditions: Enteritis; Bleeding

Summary: 1. balloon-assisted enteroscopy (bae) is a new tool to investigate small intestinal diseases. 2. deep enteroscopy made possible by balloon expansion and manipulation of small intestines. 3. however, whether intestinal barrier injured during bae predispose patients to bacteremia or clinical relevant infection is not studied. 4. we will also examine relevant patient factors.

the newly developed balloon-assisted enteroscopy systems allow insertion of the enteroscopy deeply into the small intestines by fixation of the soft, redundant small intestines with an inflatable balloon over the tip of the overtube. however, the inflation of balloon might stimulate the intestinal mucosa, and the deep manipulation of intestinal segments might also compromise the intestinal barrier function. according to our preliminary experience of balloon-assisted enteroscopy (which is among the first groups in taiwan), we experienced a significant case of suspected post-procedural bactermia patient. besides, there is also a published case report from the uk reporting streptococcus milleri bacteremia which is suspected as bacterial translocation after balloon-assisted enteroscopy. however, currently there is no original study focusing on the intestinal barrier / permeability defects or bacterial translocation. this is a timely and novel research topic in the current developing era of balloon-assisted enteroscopy.

Eligibility criteria:
inclusion criteria: * adult patients with clinical suspicions of small intestinal lesions in need of balloon-assisted enteroscopy examinations * signed written informed consents exclusion criteria: * patients with active infection or receiving systemic (oral or intravenous) antibiotics within recent 3 months (this may decrease effect of bacterial translocation) or taking drugs that may affect renal function within 3 months * unstable health condition for balloon-assisted enteroscopy (unstable hemodynamics, severe cardiopulmonary compromise) * pregnancy * known allergy to lactulose, mannitol * refuse to sign written informed consent of this study. * patients would be advised to hold prokinetic agents

Keywords: balloon enteroscopy bacteremia
remote electronic patient monitoring in gastrointestinal cancer

Conditions: Gastrointestinal Cancer

Summary: the goal of this research study is to evaluate a program that involves remote electronic monitoring of vital signs and symptoms of patients with gastrointestinal cancer who were recently hospitalized at massachusetts general hospital or presented to the oncology clinic for an unplanned, urgent visit.

patients with gastrointestinal cancer often experience troublesome symptoms and side effects related to the cancer and its treatment. unfortunately, patients commonly require hospital admission or urgent clinic visits to help manage uncontrolled symptoms. for this study, the investigators seek to determine if a program that entails remote electronic monitoring may improve the overall care experience of patients with gastrointestinal cancer who have urgent care needs. the investigators are asking the participants to take part in this research study because the participants are currently hospitalized at massachusetts general hospital or recently presented to the oncology clinic for an urgent visit, and are receiving treatment at the cancer center. the goal of this study is to test a program that involves remote electronic monitoring of vital signs and patient-reported health outcomes. this study is a pilot study, and the investigators are evaluating the feasibility of delivering the program, the acceptability and satisfaction with the program, changes in the quality of life and symptoms of patients who receive the program, as well as the frequency of urgent hospital visits while the patient is in the program.

Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosed with gastrointestinal cancer * hospitalized at massachusetts general hospital (mgh) or presenting to the ambulatory mgh oncology clinic for an unplanned, urgent visit * planning to receive outpatient care at the mgh cancer center * ability to read and respond to questions in english exclusion criteria: * uncontrolled psychiatric illness or impaired cognition that would interfere with completing study procedures * enrolled in hospice * planning to be discharged to any location other than their home
scoring system for inhalation injury

Conditions: Inhalation Injury

Summary: the goal of this multicenter study is to develop a standardized scoring system for inhalation injury that can be used both to quantify and predict injury severity inhalation injury in adults over 18 years of age. a model will be developed based on clinical, radiographic, bronchoscopic, and biochemical parameters that will predict the severity of inhalation injury with greater than 80% predictive accuracy

the goal of this multicenter study is to develop a standardized scoring system for inhalation injury that can be used both to quantify and predict injury severity inhalation injury in adults over 18 years of age. a model will be developed based on clinical, radiographic, bronchoscopic, and biochemical parameters that will predict the severity of inhalation injury with greater than 80% predictive accuracy

Eligibility criteria:
inclusion criteria: * injury consistent with inhalation of smoke or products of combustion * requires intubation within 24 hours of injury * meets one of the following 4 criteria 1. history of closed space injury 2. carbonaceous sputum 3. elevated carboxyhemoglobin 4. dx of inhalation injury is considered likely by investigator exclusion criteria: * ≤ 17 years of age * prisoner

Keywords: inhalation injury, smoke inhalation injury, acute
ofloxacin concentration-toxicity relationship in the elderly

Conditions: Ofloxacin; Bone and Joint Infection; Therapeutic Drug Monitoring; Adverse Drug Reactions

Summary: ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. however, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. the occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. however, the serum concentration-toxicity relationship has not yet been determined. the purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.


Eligibility criteria:
inclusion criteria: * patients aged over 65 years hospitalized at the university hospital of amiens for an uncomplicated bone and joint infections * indication for oral switch to ofloxacin exclusion criteria: * patient refusing to participate in the study * patient under guardianship or curators or deprived of public rights * any liver or biliary injury * any contraindications to ofloxacin

Keywords: ofloxacin bone and joint infection therapeutic drug monitoring adverse drug reactions
nutrition education in cardiac rehabilitation

Conditions: Cardiometabolic Syndrome

Summary: coronary heart disease is one of the united kingdom's biggest killers. in the uk alone 175,000 myocardial infarctions are recorded annually. to lower the financial burden on the national health service, cardiac rehabilitation facilitates a systematic and multidisciplinary approach to secondary prevention aimed to improve functional capacity and health-related quality of life, lower rehospitalisation rates and reduce all-cause and cardiovascular mortality with exercise training being the cornerstones. the effectiveness of cardiac rehabilitation programmes in delivering effective secondary prevention has long been established. improvements are recorded in cardiovascular endurance, muscular strength and endurance, balance, co-ordination, and quality of life. however, many patients see little or no change in body mass and body mass index, an independent risk factor for coronary heart disease. interestingly, the inclusion of nutrition education is rarely reported within specific cardiac rehabilitation settings, therefore evidence of best practice remains elusive and warrants further investigation. the aim of this trial is to compare: * usual care - where patients access to two exercise classes per week and all facilities normally available as part of their cardiac rehabilitation programme. patients in this group will undergo this approach for 12-weeks. * usual care + biggest loser - in addition to usual care, patients in this group took part in the 'biggest loser' program in which the patients attended weekly sessions outside of their usual exercise class times. each session follows a specific theme based on british heart foundation healthy eating guidelines. participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks. * usual care + new education programme. in addition to usual care, the same weekly topics as the biggest loser are covered yet with bespoke information regarding portion sizes and recipes provided each week and patients given a challenge each week in relation to the topic being covered e.g. include more vegetables. participants will undergo this approach for 6-weeks and then switch to usual care for 6-weeks. patients will be tested at baseline, 6-weeks and 12-weeks.


Eligibility criteria:
inclusion criteria: * able to give informed consent * engaged in phase iv cardiac rehabilitation program * patient has read and understood the patient information sheet * clinically stable (symptoms and medication) exclusion criteria: * clinically unstable (symptoms and medication)
exhaled breath condensate analysis in mechanically ventilated patients

Conditions: Acute Respiratory Failure; Critical Illness

Summary: mechanically ventilated intensive care patients will be sampled for a small amount of exhaled breath condensate from the ventilator circuit and for venous blood. proteomic analysis of the exhaled breath condensate will be performed using mass spectrometry and in the blood sample, corresponding changes in the dna, rna, proteins, and metabolites will be studied. resulting profiles will be correlated with routinely monitored parameters in order to identify patterns corresponding to various pathologies in order to enable their early detection.

exhaled breath condensate (ebc) is a product of gas exchange in the lungs. it contains plethora of substances of possible diagnostic value and its composition is likely to change rapidly in response to the development of pathological conditions, especially in the lungs. mechanically ventilated intensive care patients with various pathological conditions will be sampled for a small amount of ebc from the ventilator circuit and for venous blood. a sampling method not affecting relevant parameters of mechanical ventilation will be developed and standardised. ebc samples will be frozen and after processing, proteomic analyses will be performed using mass spectrometry. in the blood sample, corresponding changes in the dna, rna, proteins, and metabolites will be studied using molecular biological methods. resulting profiles will be correlated with routinely monitored parameters (such as inflammation markers, microbiological findings and mechanical ventilation parameters) with the aim of finding patterns corresponding to the early stages of various pathological conditions focusing on lung tissue. identification of patterns specific to initial stages of lung and other organ pathologies would enable their early treatment possibly shortening mechanical ventilation/icu stay and reducing morbidity/mortality.

Eligibility criteria:
inclusion criteria: intensive care setting mechanical ventilation ventilator/ventilator circuit technically suitable for sampling of exhaled breath condensate exclusion criteria: mechanical ventilation challenging to the extent that the insertion of the sampling kit into the ventilator circuit would substantially increase the risk for respiratory deterioration

Keywords: exhaled breath condensate proteomics genomics mechanical ventilation acute respiratory failure lung injury intensive care
risk factors for postoperative spinal epidural hematoma following posterior thoracic spinal surgery in a single institute

Conditions: Spinal Epidural Hematoma; Thoracic Surgery

Summary: this is a retrospective, observational single-center study. the studies is to investigate the incidence of posterior epidural spinal hematoma(pseh) and recognize the risk factors for it in a cohort of patients undergoing posterior thoracic surgery in isolation.

the study enrolled patients from january 2010 to december 2019, patients who developed pseh after posterior thoracic surgery and underwent the hematoma evacuation. for each pseh patients, 2 or 3 controls who did not develop the pseh, underwent the same procedures of similar complexity at the same section of thoracic spine in the same period were collected. the preoperative and intraoperative factors, blood pressure related factors and radiographic parameters were collected to identify possible risk factors by comparing between two groups.

Eligibility criteria:
inclusion criteria: subjects satisfying the following criteria will be considered eligible for enrollment in this study: 1. patient is ≥ 18 years and \< 80 years of age; 2. patient who received thoracic decompression surgery via posterior approach 3. patient who diagnosed as symptomatic spinal epidural haematoma and received revision surgery. exclusion criteria: 1. thoracic spinal stenosis caused by trauma, tumor, infectious, deformity and other disease; 2. symptomatic spinal epidural haematoma happened at cervicothoracic and thoracolumbar junction; 3. initial surgeries were performed at other hospital; 4. incomplete clinical data.

Keywords: symptomatic spinal epidural hematoma posterior thoracic surgery local kyphosis angle occupying ratio of cross-sectional area cerebrospinal fluid leakage.
an international pulmonary embolism registry using ekos

Conditions: Pulmonary Embolism and Thrombosis

Summary: this registry is designed to understand acoustic pulse thrombolysis (apt) treatment regimens used as standard of care globally for pulmonary embolism. the registry will include individuals who have already received the apt treatment and those that will undergo apt treatment.

for the prospective arm of the registry, a physician will have selected the apt procedure for the treatment of pulmonary embolism. the apt treatment and follow-up assessments are per clinical judgement and institutional standard of care which may vary at each clinical site. for the retrospective arm of the registry, the investigators will gather data from consecutive cases of individuals who received the apt treatment for pulmonary embolism. specific baseline, treatment, and long-term health information is collected and de-identified.

Eligibility criteria:
retrospective inclusion criteria: * treated with apt procedure between january 1, 2014 and one year prior to site activation * rv/lv ≥ 1.0 from diagnostic computed tomographic angiography (cta) or echocardiogram * pe symptom duration ≤ 14 days * troponin elevation retrospective exclusion criteria: * enrollment into the optalyse pe study prospective inclusion criteria: * male or female ≥ 18 years of age and ≤ 80 years of age * rv/lv ≥ 1.0 from diagnostic computed tomographic angiography (cta) or echocardiogram * pe symptom duration ≤ 14 days * troponin elevation * signed informed consent obtained from participant or legally authorized representative * investigator has selected the ekos device to treat participant with massive or submassive pulmonary embolism prospective exclusion criteria: * high-risk for catastrophic bleeding * life expectancy \< one year

Keywords: venous thromboembolism
phase ii study of shr-1210(anti-pd-1 antibody) combination with apatinib versus pemetrexed and carboplatin in subjects with kras mutant stage iv non-squamous non-small cell lung cancer

Conditions: NSCLC Stage IV; KRAS Gene Mutation; PD-1 Antibody; Chemotherapy Effect

Summary: this is a randomized, open-label, multi-center, phase ii trial to evaluate the efficacy and safety of shr-1210 plus apatinib mesylate versus pemetrexed and carboplatin in subjects with kras mutant stage iv non-squamous non-small cell lung cancer


Eligibility criteria:
inclusion criteria: 1. subjects with histopathological diagnosis of adenocarcinoma non-small cell lung cancer (nsclc) and clinical stage iv 2. has not received prior systemic treatment for metastatic nsclc. 3. has a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance status 4. confirmes by the central laboratory as kras gene mutation 5. has archived tumor tissue samples 6. subject must have a measurable target lesion based on recist v1.1 . 7. women of childbearing age must undergo a serological pregnancy test within 3 days before the first dose with negative results. female subjects of reproductive age and male subjects whose spouse is a woman of reproductive age must agree to effective contraception within 180 days after the study period and the last dose of the study drug. 8. subjects should be voluntarily participate in clinical studies and informed consent should be signed. exclusion criteria: 1. active brain metastases and meningeal metastasis 2. uncontrollable tumor-related pain 3. massive pleural effusion, peritoneal effusion or pericardial effusion which cannot be controlled by repeated drainage; 4. radiotherapy to lung that is \>30 gy within 24 weeks before the first dose, 5. imaging (ct or mri) showed that the tumor invading the large vessels 6. known egfr/alk mutation. 7. subjects with any known or suspected autoimmune diseases 8. subjects with known or suspected interstitial pneumonia; 9. subjects with severe cardiovascular and cerebrovascular diseases 10. arteriovenous thrombosis events, such as deep vein thrombosis and pulmonary embolism, occurred within 3 months; 11. female subjects who are pregnant or lactation or who plan to be pregnant during the study period; 12. positive hiv test; 13. active hepatitis b 14. evidence of active tb infection within 1 year before first dose; 15. severe infection occurred within 4 weeks before the first dose 16. patients with clinically significant bleeding symptoms or with obvious bleeding tendency in the first month 17. subjects who is on systemic immunogenic agents; 18. a history of severe allergic reactions to other monoclonal antibodies/fusion proteins; 19. history of severe allergic reactions to carboplatin or pemetrexed or their preventive drugs;
a study of the expression of nogo and reticulon genes in skeletal muscle of patients with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: this is a study of the expression of nogo and reticulon genes in the skeletal muscle of patients with amyotrophic lateral sclerosis (als).


Eligibility criteria:
inclusion criteria: * patients with definite als * males or females * age \> 18 exclusion criteria: * patients with other neuromuscular affections

Keywords: amyotrophic lateral sclerosis nogo gene reticulon genes
to compare the efficacy of combined tenofovir plus telbivudine vs tenofovir alone in patients with spontaneous reactivation of hepatitis b

Conditions: Spontaneous Reactivation of Hepatitis B

Summary: the relevant data will be prospectively collected included patient demographics, clinical, all laboratory variables including virological tests, genotyping by direct sequencing, abdominal ultrasound, and upper gastrointestinal (gi) endoscopy. trans jugular liver biopsy (tjlb) and hepatic venous pressure gradient (hvpg) will be done in patients when it was not evident whether the underlying liver disease was chronic based on clinical, biochemical, radiological investigations, and upper gi endoscopy. severity of the liver disease will be assessed by child-turcotte pugh score (ctp) and model for end stage liver disease (meld) score.


Eligibility criteria:
inclusion criteria: * reactivation of chb characterized by a rise in alt level \>5 times upper limit of normal along with hbv dna level \>10\^5 copies/ ml (\> 1.8 x 10\^4 iu/ml). exclusion criteria: 1. superinfection with other viruses (hepatitis e, a, d, or c) 2. other causes of chronic liver failure 3. coexistent hepatocellular carcinoma (hcc) 4. portal vein thrombosis 5. coexistent renal impairment 6. pregnancy 7. coinfection with human immunodeficiency virus (hiv) 8. patients who had received a previous course of any antiviral, immunomodulator or cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at least the preceding 12 months.
effect of tdcs along with relaxation technique on anxiety level in students preparing for competitive exams

Conditions: Anxiety

Summary: anxiety is one of the most significant obstacles to academic success. when stress is interpreted negatively or becomes overwhelming, it causes anxiety before and during examinations, which in turn impacts students' academic performance. the difficulty in managing severely associated anxiousness enhances the demand for nibs. it is a unique approach that has the potential to alleviate anxiety by modifying cortical excitability whereas relaxation breaks the vicious cycle of pain caused by muscular stress, circulatory illness, and metabolic by-products alterations. the main purpose is to evaluate whether tdcs along with relaxation technique reduces the anxiety level in competitive exam students. total 46 students are recruited and randomly allocating in experimental and control group. the subjects in the experimental group are going to receive 9 tdcs sessions (2ma, anode placed on the dlfpc of left side and cathode on right supraorbital cortex for 20 min) along with relaxation technique. subjects in the control group are going to receive 9 sessions of relaxation. the csai-2r scale is used as an outcome measure. samples completed the csai-2r scale before and following the intervention. the data will be analyzed using spss 26.0 software.


Eligibility criteria:
inclusion criteria: • both male and female students. * competitive exam students only. * age group between 15 years to 18 years. * willingness to take part in the research. exclusion criteria: • seizure disorder * non-corporative students * skin irritation

Keywords: anxiety, tdcs, relaxation, competitive exam students, 2ma, csai-2r